Navigation Links
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus

ct Us" section of the Company's Web site, www.hgsi.com/products/request.html, or by calling (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon, BLyS and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

HGS Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with planned facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

CONTACT: Jerry Parrott, Vice President, Corporate C
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
Post Your Comments:
(Date:12/16/2009)... Dec. 16 Medlytix, a national healthcare ... a key half-billion dollar milestone - the total ... provided in financial assistance to more than a ... of properly classifying charity care - in less ... of these hospitals enhanced their bottom lines and ...
(Date:12/16/2009)... 16 Ethicon, Inc., a Johnson & ... a worldwide leader in surgical care, and Acclarent, ... to designing, developing and commercializing devices that address ... today announced a definitive merger agreement whereby Ethicon ... approximately $785 million net of estimated cash on ...
(Date:12/16/2009)... 16 Hospira, Inc. (NYSE: HSP ... company, today announced that it will host a conference ... and projections for 2010 on Thursday, Feb. 4, 2010, ... release its fourth-quarter and full-year 2009 results earlier that ... conference call. ,, A live webcast of the conference ...
Breaking Medicine Technology:Healthcare Scoring System Allows Hospitals To Increase Charity Care 2Healthcare Scoring System Allows Hospitals To Increase Charity Care 3Healthcare Scoring System Allows Hospitals To Increase Charity Care 4Ethicon Announces Definitive Agreement to Acquire Acclarent 2Ethicon Announces Definitive Agreement to Acquire Acclarent 3Ethicon Announces Definitive Agreement to Acquire Acclarent 4Dee Snider Leads 2009 March of Dimes Bikers for Babies 28R 29 48644 1Dee Snider Leads 2009 March of Dimes Bikers for Babies 28R 29 48644 2Oncology Program at Texas Health Dallas Receives Outstanding Achievement Award 48641 1Oncology Program at Texas Health Dallas Receives Outstanding Achievement Award 48641 2Protein Branded As Culprit in Mad Cow Disease 48638 1Protein Branded As Culprit in Mad Cow Disease 48638 2
... The Society of Gynecologic Oncologists (SGO) and the American ... a breast disease fellowship training program for gynecologic oncologists. ... the program provides support for a gynecologic oncologist to ... treatment of breast cancer and related disease. "As ...
... today announced that it has received clearance from ... the U.K. Medicines and Healthcare products Regulatory Agency ... AeroTrial(TM), of inhaled dry powder Aerovant in patients ... United States for AeroTrial, a double-blind, randomized, placebo-controlled, ...
Other Medicine Technology:SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists 2SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists 3Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma 2Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma 3
(Date:12/17/2009)... Neurological Stress Reduction Therapy or NSRTSM is found very effective ... such as allergies, asthma, migraines, chronic fatigue and a wide ... the country are using this holistic therapy including over 50 ... ... Allentown, PA (Vocus) December 16, 2009 -- BioVeda ...
(Date:12/16/2009)... -- If proposed health care legislation is enacted, ... insurance system. Approximately 18.4 million Californians and 161 ... upon employer-based insurance for their health care coverage. ... reform legislation entail specific requirements for employer-based insurance. ... for firms that currently comply with most new ...
(Date:12/16/2009)... 16 New Enterprise Associates, Inc. (NEA), ... that one of its portfolio companies, Acclarent, Inc., ... acquired by Ethicon, Inc., a Johnson & Johnson ... million (net of estimated cash on hand at ... to designing, developing and commercializing devices that address ...
(Date:12/16/2009)... -- Allscripts (Nasdaq: MDRX ) announced today ... the three and six months ended November 30, ... January 11, 2010. Allscripts management will host a ... earnings and other information at 8:30 AM Eastern ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts fiscal second quarter ...
(Date:12/16/2009)... Averting second, possibly deadly, attack is long-term goal, researchers ... Researchers have developed a tool to predict whether a ... of a first stroke. , "This is an important ... have a second stroke soon after a first stroke ... Dr. Hakan Ay, of Massachusetts General Hospital and Harvard ...
Breaking Medicine News(10 mins):Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 5Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:New Stroke Tool May Predict Early Recurrence 2
... have asked the World Health Organization to investigate the possibility ... of bird flu//. They are already ready to invest $1.9bn ... virus is already being done. ,Tony Blair while ... preparedness for an outbreak of bird flu insisted that precautions ...
... of neurobiology at the University of California, Irvine (UCI) ... that the experimental drug// AF267B is effective against both ... mice. ,This compound (AF267B) curbs both the ... well as another lesion, the tangles of protein called ...
... PhD, of the University of Reading in England, has said ... or antiperspirants and breast cancer. She says that he aluminum-based ... body.// ,"Lifetime exposure to estrogen is the risk ... said. "If the aluminum salts in antiperspirants enter the body ...
... as about 3,000 people in the steel town were affected by ... in a small group at a slum// cluster in Panposh on ... then, it has rapidly spread to other parts of the town. ... acute colic pain, said a senior district health official. ...
... A research team has now established that a delayed-release ... may be associated with less abuse, when compared to ... the form of an oral formulation have not been ... drug abuse. The results of the study can be ...
... For those who instantly saw it as a half full glass, ... your body will promote overall well-being// and also lower cardiovascular risk ... men in the age group of 64 to 84, the most ... and demeanor had been tracked for nearly 15 years. This study ...
Other Medicine News:Health News:Experimental Alzheimer’s Drug curbs the disease in mic 2Health News:Concerta, Drug Used in ADHD Treatment Less Likely To Result In Abuse 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: